Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2003

View Archived Issues

4SC and Boehringer Ingelheim sign drug discovery agreement

New series of antifungal azoles in early development at Aventis

BioTie researchers present new inhibitors of VAP-1 SSAO

New inhibitors of glyceraldehyde-3-phosphate dehydrogenase and their use in cancer

Ortho-McNeil patent covers antiepileptic topiramate salts

Inhibitors of aP2 and their use in diabetes and lipid disorders claimed by BMS

Exelixis and Protein Design Labs' cancer antibody research collaboration progresses

Albany Molecular Research provides chemistry expertise to Affinium

Progress on several fronts at Amersham

Efficacy reported for G-3139-containing chemotherapy in refractory/relapsed acute leukemia

AGI-1067 equally effective and safer than probucol after PCI

Novel anti-HCV NS3 protease agents presented by Vertex

Novel NK1 antagonists and their use covered by Solvay patent

New tetracyclines discovered by Paratek scientists

FDA approves Oxytrol for overactive bladder

Chiron plans U.S.-based phase III trial for Menjugate

Medarex and Ferric collaborate on therapeutic antibody development

SkyePharma achieves proof of principle for Biosphere technology

Microscience's oral typhoid vaccine is safe and immunogenic

Emisphere reports phase IIa data for oral calcitonin

Shire licenses MethyPatch from Noven

P2Y2 agonists and their potential in vaginal dryness in postmenopausal women

Variations in the efficacy of TNP-470 according to the time of day administered

Inhibitor of NFkB activation suppresses growth of hormone-refractory prostate cancer

Anxiolytic-like effects without sedation or ataxia observed for DMP-696 in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...